{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ANDREW ROSS SORKIN", "person": [{"middlename": "Ross", "firstname": "Andrew", "lastname": "SORKIN", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": "Andrew Ross Sorkin DealBook column examines role of activist investment firm ValueAct, founded by Jeffrey Ubben, in designing executive compensation policies at Valeant Pharmaceuticals; critics suggest ValueAct's support of J Michael Pearson as Valeant's chief executive laid path for aggressive accounting practices that, along with decision to significantly increase drug prices, have sparked federal investigations. ", "type_of_material": "News", "word_count": "1095", "lead_paragraph": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "pub_date": "2016-03-29T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "ValueAct Pays a Price for Its Supporting Role at Valeant", "content_kicker": "DealBook", "print_headline": "Another Firm Pays a Price for Its Supporting Role at Valeant", "kicker": "DealBook Column"}, "snippet": "ValueAct deserves credit \u2014 or blame \u2014 for virtually everything that happened to Valeant Pharmaceuticals over nearly the last decade.", "multimedia": [{"height": 126, "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbWide-v2.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 899, "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "899", "xlarge": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/03/29/business/29dbsorkin-sub/29dbsorkin-sub-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/03/29/business/dealbook/valueact-pays-a-price-for-its-supporting-role-at-valeant.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Executive Compensation", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "ValueAct Capital Partners", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Ubben, Jeffrey W", "name": "persons"}, {"rank": "5", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "6", "is_major": "N", "value": "Ackman, William A", "name": "persons"}, {"rank": "7", "is_major": "N", "value": "Accounting and Accountants", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "56f9d31538f0d874a87cb0c6", "source": "The New York Times"}